Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Areva P0014
- Development stage
- Preclinical
- Lead developer
- Areva Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
Areva P0014 is an investigational small molecule injectable drug candidate developed by Areva Pharmaceuticals. It is currently in the late stages of regulatory preparation, with an expected New Drug Application (NDA) or Biologics License Application (BLA) milestone projected for the second quarter of 2027. The product is formulated as a 25 mg/mL injection and is currently patent-pending. Although the specific therapeutic target and indication have not been publicly disclosed, Areva Pharmaceuticals focuses on the development of injectable pharmaceuticals for oncology and supportive care, suggesting the drug is intended for use in these clinical areas.
Beyond the preview
Go deeper on Areva P0014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Areva P0014.